Gerard Evan
Affiliations: | Biomedical Sciences | University of California, San Francisco, San Francisco, CA |
Area:
Neuroscience BiologyGoogle:
"Gerard Evan"Mean distance: 35622
Children
Sign in to add trainee| Nichole Reyes | grad student | 2011 | UCSF |
| Rebecca Lock | grad student | 2012 | UCSF |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dhillon P, Evan G. (2019) In conversation with Gerard Evan. The Febs Journal. 286: 4824-4831 |
| Propper D, Han H, Hoff DV, et al. (2019) Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer Cancer Research. 79 |
| Azzarelli R, Hurley C, Sznurkowska MK, et al. (2017) Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation. Developmental Cell |
| Jung LA, Gebhardt A, Koelmel W, et al. (2016) OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene |
| Brindle NR, Joyce JA, Rostker F, et al. (2015) Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer. Plos One. 10: e0120348 |
| Correia L, Farah H, Rassl D, et al. (2015) S102 SOX2 initiates carcinogenesis in a novel organotypic model of bronchial dysplasia Thorax. 70 |
| Muthalagu N, Junttila MR, Wiese KE, et al. (2014) BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports. 8: 1347-53 |
| Grayson AR, Walsh EM, Cameron MJ, et al. (2014) MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma Oncogene. 33: 1736-1742 |
| Farkas C, Martins CP, Escobar D, et al. (2013) Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. Plos One. 8: e73817 |
| Walsh EM, Grayson AR, Cameron MJ, et al. (2013) Abstract B39: MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma Molecular Cancer Therapeutics. 12 |